{"id":511966,"date":"2021-07-12T16:04:06","date_gmt":"2021-07-12T20:04:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\/"},"modified":"2021-07-12T16:04:06","modified_gmt":"2021-07-12T20:04:06","slug":"forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\/","title":{"rendered":"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules <\/b><\/p>\n<p>TORRANCE, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nForte Biosciences, Inc. (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fortebiorx.com%2F&amp;esheet=52458061&amp;newsitemid=20210712005233&amp;lan=en-US&amp;anchor=www.fortebiorx.com&amp;index=1&amp;md5=cceafe7701a1e2b6a994eff68969fe00\">www.fortebiorx.com<\/a>) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.\n<\/p>\n<p>\nIn accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte\u2019s Board of Directors approved the grant of an equity award to purchase 15,000 shares of common stock to a new non-executive employee as a material inducement to such individual\u2019s accepting employment with the Company, with such award vesting over four years, with twenty-five percent vesting on the one-year anniversary of the grant date and the remaining seventy-five percent vesting in equal monthly increments over the succeeding thirty-six months, subject to the individual\u2019s continuous employment through each vesting date.\n<\/p>\n<p>\nThe Inducement Award was made outside of Forte\u2019s current equity plan, under Forte\u2019s 2020 Inducement Equity Incentive Plan and related award agreements, but will have terms and conditions generally consistent with those of Forte\u2019s 2021 Equity Incentive Plan.\n<\/p>\n<p><b>About Forte Biosciences, Inc.<\/b><\/p>\n<p>\nForte Biosciences, Inc. is a clinical-stage, biopharmaceutical company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. There is a significant unmet need for safe and effective therapies particularly for pediatric atopic dermatitis (\u201cAD\u201d) patients. To date, a Phase 1\/2a study has been completed with pediatric and adult patients 3 years of age and older, demonstrating compelling safety and activity in patients with mild, moderate and severe disease, across age groups including pediatrics and adults, and across key endpoints.\n<\/p>\n<p>\nIn September 2020, Forte initiated a multi-center, placebo-controlled clinical trial of FB-401 which has enrolled pediatric, adolescent and adult AD subjects aged 2 years of age and older. Additional information about our Phase 2 trial can be found at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fclinicaltrials.gov%2F&amp;esheet=52458061&amp;newsitemid=20210712005233&amp;lan=en-US&amp;anchor=ClinicalTrials.gov&amp;index=2&amp;md5=d195084ce96f209067ac785e5c08c5ac\">ClinicalTrials.gov<\/a> using the identifier NCT04504279.\n<\/p>\n<p><b>Forward Looking Statements<\/b><\/p>\n<p>\nForte cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential\u201d or \u201ccontinue\u201d or the negatives of these terms or other similar expressions. These statements are based on the Company\u2019s current beliefs and expectations. Forward looking statements include statements regarding Forte\u2019s beliefs, goals, intentions and expectations, and include statements regarding its ability to continue to advance its product candidates through the development process and achieve potential clinical development milestones in the future. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: risks related to Forte\u2019s ability to obtain sufficient additional capital to continue to advance the company\u2019s product candidates and preclinical programs; unexpected costs, charges or expenses; uncertainties associated with the clinical development and regulatory approval of Forte\u2019s product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; the risk that interim results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; the risk that unforeseen adverse reactions or side effects may occur in the course of developing and testing product candidates; and risks associated with the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Forte undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.\n<\/p>\n<p>\nSource: Forte Biosciences, Inc.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210712005233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210712005233\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210712005233\/en\/<\/a><\/span><\/p>\n<p>\nInvestors:<br \/>\n<br \/>Forte Biosciences, Inc.<br \/>\n<br \/>Paul Wagner, CEO<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@fortebiorx.com\">investors@fortebiorx.com<\/a><\/p>\n<p>\nLifeSci Advisors<br \/>\n<br \/>Mike Moyer, Managing Director<br \/>\n<br \/>617.308.4306<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:mmoyer@lifesciadvisors.com\">mmoyer@lifesciadvisors.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules TORRANCE, Calif.&#8211;(BUSINESS WIRE)&#8211; Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte\u2019s Board of Directors approved the grant of an equity award to purchase 15,000 shares of common stock to a new non-executive employee as a material inducement to such individual\u2019s accepting employment with the Company, with such award vesting over four years, with twenty-five percent vesting on the one-year anniversary of the grant date and the remaining seventy-five percent vesting in equal monthly increments over the succeeding thirty-six months, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-511966","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules TORRANCE, Calif.&#8211;(BUSINESS WIRE)&#8211; Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte\u2019s Board of Directors approved the grant of an equity award to purchase 15,000 shares of common stock to a new non-executive employee as a material inducement to such individual\u2019s accepting employment with the Company, with such award vesting over four years, with twenty-five percent vesting on the one-year anniversary of the grant date and the remaining seventy-five percent vesting in equal monthly increments over the succeeding thirty-six months, &hellip; Continue reading &quot;Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-12T20:04:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210712005233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules\",\"datePublished\":\"2021-07-12T20:04:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\\\/\"},\"wordCount\":740,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210712005233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\\\/\",\"name\":\"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210712005233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-07-12T20:04:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210712005233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210712005233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\/","og_locale":"en_US","og_type":"article","og_title":"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules - Market Newsdesk","og_description":"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules TORRANCE, Calif.&#8211;(BUSINESS WIRE)&#8211; Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte\u2019s Board of Directors approved the grant of an equity award to purchase 15,000 shares of common stock to a new non-executive employee as a material inducement to such individual\u2019s accepting employment with the Company, with such award vesting over four years, with twenty-five percent vesting on the one-year anniversary of the grant date and the remaining seventy-five percent vesting in equal monthly increments over the succeeding thirty-six months, &hellip; Continue reading \"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-12T20:04:06+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210712005233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules","datePublished":"2021-07-12T20:04:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\/"},"wordCount":740,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210712005233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\/","name":"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210712005233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-07-12T20:04:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210712005233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210712005233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/forte-biosciences-inc-reports-inducement-grants-under-nasdaq-listing-rules-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/511966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=511966"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/511966\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=511966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=511966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=511966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}